| 000 | 01564 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250511180521.0 | ||
| 264 | 0 | _c19921127 | |
| 008 | 199211s 0 0 eng d | ||
| 022 | _a0022-2623 | ||
| 024 | 7 |
_a10.1021/jm00099a020 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEvans, B E | |
| 245 | 0 | 0 |
_aOrally active, nonpeptide oxytocin antagonists. _h[electronic resource] |
| 260 |
_bJournal of medicinal chemistry _cOct 1992 |
||
| 300 |
_a3919-27 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aMagnetic Resonance Spectroscopy |
| 650 | 0 | 4 |
_aObstetric Labor, Premature _xdrug therapy |
| 650 | 0 | 4 |
_aOxytocin _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPiperidines _xadministration & dosage |
| 650 | 0 | 4 | _aPregnancy |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 |
_aReceptors, Angiotensin _xmetabolism |
| 650 | 0 | 4 | _aReceptors, Oxytocin |
| 650 | 0 | 4 |
_aReceptors, Vasopressin _xmetabolism |
| 650 | 0 | 4 |
_aSpiro Compounds _xadministration & dosage |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 700 | 1 | _aLeighton, J L | |
| 700 | 1 | _aRittle, K E | |
| 700 | 1 | _aGilbert, K F | |
| 700 | 1 | _aLundell, G F | |
| 700 | 1 | _aGould, N P | |
| 700 | 1 | _aHobbs, D W | |
| 700 | 1 | _aDiPardo, R M | |
| 700 | 1 | _aVeber, D F | |
| 700 | 1 | _aPettibone, D J | |
| 773 | 0 |
_tJournal of medicinal chemistry _gvol. 35 _gno. 21 _gp. 3919-27 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1021/jm00099a020 _zAvailable from publisher's website |
| 999 |
_c1337972 _d1337972 |
||